Features | Partner Sites | Information | LinkXpress
Sign In
KOREA E & EX
Schiller
Ampronix

Blood Test Measures Hodgkin’s Chemotherapy Success

By HospiMedica International staff writers
Posted on 06 Mar 2013
A cheap and easy to use diagnostic test helps determine the success of chemotherapy in patients enduring Hodgkin’s lymphoma (HL).

Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.

The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.

“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”

Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.

Related Links:

Queensland Institute of Medical Research
University of Melbourne



Inditherm
Harloff
JD Honigberg International

Channels

Surgical Techniques

view channel

Thinner Minilaparoscopic Instruments Ease Procedural Tasks

A new study that examined surgeons’ perceptions of transanal endoscopic microsurgery (TEM) using minilaparoscopic instruments reveals that thinner is better. Researchers at the University of Sao Paulo (USP; Brazil), the Federal University of Pernambuco (Recife, Brazil), and other institutions hypothesized that visualization... Read more

Women's Health

view channel
Image: The Bloom Ring fertility app monitoring core temperature (Photo courtesy of Prima-Temp).

Subtle Temperature Sensor Heightens Fertility Awareness

A new self-inserted core temperature sensor helps women detect when a fertility “window of opportunity” opens. The Bloom Ring is a core body temperature fertility sensor that is inserted by the user... Read more

Health IT

view channel
Image: Study authors Mike Kolber, Christina Korownyck, and Mike Allan (Photo courtesy of the University of Alberta).

Viewers Cautioned on Televised Medical Talk Show Recommendations

A new study warns that the public should be skeptical of recommendations made on mainstream television medical talk shows, as they often lack adequate evidence or are contradicted by the best available evidence.... Read more

Hospital News

view channel
Image: The new Parkland Memorial Hospital (Photo courtesy of Parkland Memorial Hospital).

New Parkland Memorial Hospital Nears Completion

At nearly twice the size of the current hospital, the new Parkland Memorial Hospital (Dallas, TX, USA) will be one of the first “digital hospitals” in the United States. The new hospital, built at... Read more

Business

view channel

Moderate Growth Expected for Global Medical Device Market

While the global market for medical devices reached an estimated USD 361 billion in 2014, the average growth was only 3%. These are the latest findings of Kalorama Information (New York, NY, USA), an independent medical market research firm. The growth was driven by countries outside of the traditional markets that include... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.